22:48 , May 3, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Sangamo

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said CEO Milind Deshpande will step down. He will be succeeded by President and COO Joseph Truitt. Sangamo Therapeutics Inc. (NASDAQ:SGMO) said SVP and CBO Curt Herberts, III...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Lasofoxifene: Phase I data

An investigator-blinded, placebo-controlled Phase I trial in 36 healthy male volunteers showed that single doses of 1, 3, 10, 30 and 100 mg oral lasofoxifene increased testosterone levels, with the 2 highest doses increasing testosterone...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Azure Biotech Inc., Ethicor Pharma, Ligand deal

Ligand granted newco Azure an exclusive, worldwide license to develop and commercialize a new formulation of Ligand's osteoporosis drug lasofoxifene for an undisclosed women's health indication. Ligand is eligible to receive $2.7 million in development...